Sotrovimab News and Research

RSS

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

In a recent study published in The Lancet Infectious Diseases, researchers investigated the neutralization sensitivity of the emerging Omicron sub-variants, BA.2.12.1, BA.4, and BA.5.

30 Jun 2022

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

28 Jun 2022

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Researchers assessed the in vivo effectiveness of monoclonal antibodies and directly acting antiviral agents against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages.

28 Jun 2022

Exploring antigenic traits of SARS-CoV-2 Omicron BA.5 and BA.4 subvariants

Scientists analyzed the antigenic characteristics of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 and BA.4 sublineages.

27 May 2022

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

Researchers compared the efficacy of sotrovimab and molnupiravir in preventing severe COVID-19 outcomes among non-hospitalized and high-risk COVID-19 patients across England.

25 May 2022

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

A recent article posted to the bioRxiv* preprint server demonstrated structural underpinnings of the neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants by 002-S21F2, an extensive SARS-CoV-2 neutralizing antibody.

18 May 2022

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

A study, published online in the journal mAbs, describes a novel mAb, UT28K, that has promising broadly neutralizing activity against the SARS-CoV-2 virus.

15 May 2022

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

A new study analyzed the imprinted antibody responses towards the SARS-CoV-2 Omicron subvariants.

12 May 2022

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

Researchers depicted the efficacy of the SARS-CoV-2 monoclonal antibodies (mAbs) against the SARS-CoV-2 Omicron variant.

11 May 2022

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination

10 May 2022

The war against COVID-19: reinfection, vaccines, and herd immunity

A communication published in the journal Epidemiologia aimed to answer several questions concerning neutralizing antibodies against SARS-CoV-2, herd immunity, and COVID-19 vaccines.

4 May 2022

The sensitivity of Omicron subvariants to therapeutic monoclonal antibodies

A new study evaluates the sensitivity of the new Omicron subvariants (BA.2.11, BA.2.12.1, and BA.4/5) to eight therapeutic mAbs

4 May 2022

SARS-CoV-2 BA.2 poses greater risk to global health than BA.1

In a recent study published in the journal Cell, researchers investigated distinguishing virological characteristics of Omicron sub-variant BA.2.

3 May 2022

Clinical characteristics of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Researchers examined the characteristics and outcomes of COVID-19 in immunocompromised patients.

29 Apr 2022

Bebtelovimab potently neutralizes all SARS-CoV-2 variants of concern

The current study, escribes a new mAb LY-CoV1404 (bebtelovimab) from Eli Lilly, with high neutralization potency with a broad spectrum of activity across all current variants.

27 Apr 2022

Treating COVID-19 using monoclonal antibodies during pregnancy

Researchers assessed the efficiency efficacy and safety of monoclonal antibodies for treating SARS-CoV-2 during pregnancy.

25 Apr 2022

The challenges of Omicron

A new review published in sums up the position of Omicron as a potential threat to human health, especially in the context of controlling this pandemic.

25 Apr 2022

Antibody escape in SARS-CoV-2 Omicron spike protein

Researchers examined antibody escape and cross-domain stabilization in the SARS-CoV-2 Omicron spike protein.

22 Apr 2022

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

A recent study posted to the medRxiv* preprint server assessed the impact of sotrovimab treatment on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected immunocompromised (IC) patients.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022